Liu Jia, Cui Wei-guo, Sun Guo-qing, Zhu Xin-peng, Tian Sui-an, Sun Ding-yong, Yang Wen-jie, Li Ning, Zhu Qian, Wang Zhe
Institute for Prevention and Control of STD and AIDS, Henan Provincial Center for Disease Control and Prevention, Zhengzhou 450016, China.
Zhonghua Liu Xing Bing Xue Za Zhi. 2010 Sep;31(9):1013-6.
To analyze the CD4(+) T cells and virus load in HIV/AIDS affected population and to evaluate the HIV/AIDS antiretroviral therapy programs in Henan province.
"Henan HIV/AIDS Testing Laboratory Network Database" was used to collect the data on CD4(+) T cells and virus load (VL) value and corresponding information in HIV/AIDS population of Henan in 2009. Cross-sectional studies was used to study the constituent ratio of CD4(+) T cells and virus load value in individuals who had not received antiretroviral-treated (ART) and had joined first-line ART between the year of 2005 to 2008 among HIV/AIDS population of Henan.
As to these people living with HIV/AIDS that had not received ART in the first half and the second half year of 2009, the constituent ratio of individuals whose CD4(+) T cells were less than 200 cells/µl both accounted for more than 20% (χ(2) = 2.059, P = 0.151). The constituent ratio of individuals whose CD4(+) T cells were in 200 - 350 cells/µl and more than 350 cells/µl increased from 27.61% to 29.41% (χ(2) = 4.636, P = 0.031) and decreased from 51.49% to 48.60% (χ(2) = 9.767, P = 0.002), respectively. Meanwhile, we saw 34.53% and 19.65% of the patients whose virus load was > 10 000 copy/ml and > 30 000 copy/ml in this population. Patients that joined first-line ART during 2005 - 2008 showed the following results: the longer of the therapy time, the higher constituent ratio of individuals whose CD4(+) T cells were more than 350 cells/µl (χ(2) = 148.689, P < 0.001) and the lower constituent ratio of individuals of whose CD4(+) T cells were less than 200 cells/µl (χ(2) = 46.686, P < 0.001). Simultaneously, the lower constituent ratio of individuals whose viral load was less than 500 copy/ml (χ(2) = 9.066, P = 0.003) and the higher constituent ratio of individuals whose virus load was more than 10 000 copy/ml (χ(2) = 6.597, P = 0.010).
Significant curative effect had been achieved in AIDS first-line ART of Henan, but along with the increasing treatment time, the risk of treatment failure also increased. Drug resistance test and changing of treatment protocols were needed. To reach better and more efficient effects on therapy, factors as more detections and investments on ART, expanding the scope of treatment etc. were needed on those people living with HIV/AIDS that had not received ART.
分析河南省艾滋病病毒（HIV）/获得性免疫缺陷综合征（AIDS）患者人群的CD4(+) T淋巴细胞及病毒载量，并评估河南省HIV/AIDS患者抗逆转录病毒治疗方案。
利用“河南省HIV/AIDS检测实验室网络数据库”收集2009年河南省HIV/AIDS患者人群的CD4(+) T淋巴细胞及病毒载量（VL）值数据及相应信息。采用横断面研究方法，研究2005年至2008年期间河南省未接受抗逆转录病毒治疗（ART）及接受一线ART治疗的HIV/AIDS患者人群中CD4(+) T淋巴细胞及病毒载量值的构成比。
2009年上半年及下半年未接受ART治疗的HIV/AIDS患者中，CD4(+) T淋巴细胞<200个/μl的患者构成比均超过20%（χ(2)=2.059，P=0.151）。CD4(+) T淋巴细胞在200～350个/μl及>350个/μl的患者构成比分别从27.61%升至29.41%（χ(2)=4.636，P=0.031）和从51.49%降至48.60%（χ(2)=9.767，P=0.002）。同时，该人群中病毒载量>10 000拷贝/ml及>30 000拷贝/ml的患者分别占34.53%和19.65%。2005年至2008年接受一线ART治疗的患者结果显示：治疗时间越长，CD4(+) T淋巴细胞>350个/μl的患者构成比越高（χ(2)=148.689，P<0.001），CD4(+) T淋巴细胞<200个/μl的患者构成比越低（χ(2)=46.686，P<0.001）。同时，病毒载量<500拷贝/ml的患者构成比降低（χ(2)=9.066，P=0.003），病毒载量>10 000拷贝/ml的患者构成比升高（χ(2)=6.597，P=0.010）。
河南省艾滋病一线ART治疗取得显著疗效，但随着治疗时间延长，治疗失败风险增加，需进行耐药检测并调整治疗方案。对于未接受ART治疗的HIV/AIDS患者，需增加ART检测及投入、扩大治疗范围等，以达到更好更有效的治疗效果。
